Back to Trades
Boyce Sarah
DirectorCIK 0001629383
Largest Purchase
No open-market purchases in the recent filings.
Profile
- Filings
- 9
- Buy transactions
- 0
- Sell transactions
- 5
- Companies
- 3
- Active
- 2025–2026
Boyce Sarah, Director, has filed 9 SEC reports (2025–2026), spread across 3 companies, totaling $39.0M in disclosed volume. Weighing $0 bought versus $5.4M sold, the history is heavily weighted toward selling. Data is sourced from official SEC Form 3, 4, and 5 filings.
Associated Companies
Trading History
9 loaded
| Jun 26 | CTNM Contineum Therapeutics, Inc. | Boyce Sarah | Director | Award | $269.6K |
| Mar 2 | RNA Atrium Therapeutics, Inc. | Boyce Sarah | Insider | Award | $295.0K |
| Feb 27 | RNAM Avidity Biosciences, Inc. | Boyce Sarah | Insider | Disposed | $31.8M |
| Feb 26 | RNA Atrium Therapeutics, Inc. | Boyce Sarah | Insider | Other | $0 |
| Jan 23 | RNA Avidity Biosciences, Inc. | Boyce Sarah | President and CEO, Director | Sell | $1.0M |
| Jan 9 | RNA Avidity Biosciences, Inc. | Boyce Sarah | President and CEO, Director | Sell | $619.4K |
| Dec 19 | RNA Avidity Biosciences, Inc. | Boyce Sarah | President and CEO, Director | Grant | $1.1M |
| Sep 5 | RNA Avidity Biosciences, Inc. | Boyce Sarah | President and CEO, Director | Sell | $2.5M |
| Aug 29 | RNA Avidity Biosciences, Inc. | Boyce Sarah | President and CEO, Director | Sell | $1.2M |
9 filings